Tomasz Urbanowicz , Dominika Konecka-Mrówka , Jerzy Nożyński , Marek Jemielity
{"title":"Lymphocytes cross-matching as retrospective tool for hyper-acute rejection diagnosis in heart transplantation.","authors":"Tomasz Urbanowicz , Dominika Konecka-Mrówka , Jerzy Nożyński , Marek Jemielity","doi":"10.1016/j.tpr.2020.100055","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Lymphocyte cross-matching (CDC) is considered as important screening test that is unfrequently performed preoperatively in heart transplantation procedures. This test is desired to identify the risk for hyper-acute rejection in immediate postoperative period.</p></div><div><h3>Patient and method</h3><p>There were 57 patients (51 men and 6 women) in mean age of 44 +/- 14 between 2010 and 2019 screened for CDC tests. All patients were low risk for rejection including negative panel reactive antibody preoperative test. Preoperative donor's blood samples and lymph nodes were obtained during retrieval. Recipients blood samples were collected before surgery. CDC test were obtained retrospectively. Endomyocardial biopsies including immunopathological staining were performed on 6th and 14th postoperative day.</p></div><div><h3>Results</h3><p>The results obtained from cross-match test revealed 4 patients with lymphocytic T and B incompatibility (positive for cellular and humoral hyper-acute rejection) and 3 more for Lymphocytes B hyper-acute rejection (humoral rejection). All patients were hemodynamically stable. Successful therapy including high doses of polyvalent immunoglobulins and steroids parenteral infusions were proven by endomyocardial biopsies samples.</p></div><div><h3>Conclusion</h3><p>The lymphocytic cross-match testing is useful as postoperative examination. It help to find high risk patients for hyper-acute rejection. It allows for introduction immediate immunosuppressive therapeutic adjustment.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"5 3","pages":"Article 100055"},"PeriodicalIF":0.0000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tpr.2020.100055","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451959620300172","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Lymphocyte cross-matching (CDC) is considered as important screening test that is unfrequently performed preoperatively in heart transplantation procedures. This test is desired to identify the risk for hyper-acute rejection in immediate postoperative period.
Patient and method
There were 57 patients (51 men and 6 women) in mean age of 44 +/- 14 between 2010 and 2019 screened for CDC tests. All patients were low risk for rejection including negative panel reactive antibody preoperative test. Preoperative donor's blood samples and lymph nodes were obtained during retrieval. Recipients blood samples were collected before surgery. CDC test were obtained retrospectively. Endomyocardial biopsies including immunopathological staining were performed on 6th and 14th postoperative day.
Results
The results obtained from cross-match test revealed 4 patients with lymphocytic T and B incompatibility (positive for cellular and humoral hyper-acute rejection) and 3 more for Lymphocytes B hyper-acute rejection (humoral rejection). All patients were hemodynamically stable. Successful therapy including high doses of polyvalent immunoglobulins and steroids parenteral infusions were proven by endomyocardial biopsies samples.
Conclusion
The lymphocytic cross-match testing is useful as postoperative examination. It help to find high risk patients for hyper-acute rejection. It allows for introduction immediate immunosuppressive therapeutic adjustment.
期刊介绍：
To provide to national and regional audiences experiences unique to them or confirming of broader concepts originating in large controlled trials. All aspects of organ, tissue and cell transplantation clinically and experimentally. Transplantation Reports will provide in-depth representation of emerging preclinical, impactful and clinical experiences. -Original basic or clinical science articles that represent initial limited experiences as preliminary reports. -Clinical trials of therapies previously well documented in large trials but now tested in limited, special, ethnic or clinically unique patient populations. -Case studies that confirm prior reports but have occurred in patients displaying unique clinical characteristics such as ethnicities or rarely associated co-morbidities. Transplantation Reports offers these benefits: -Fast and fair peer review -Rapid, article-based publication -Unrivalled visibility and exposure for your research -Immediate, free and permanent access to your paper on Science Direct -Immediately citable using the article DOI
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
